HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICEATM Readies 5-Year Plan For Congress; Director Stokes Discusses

This article was originally published in The Rose Sheet

Executive Summary

The National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) is finalizing its five-year plan for submission to federal House and Senate appropriations committees by year-end, according to director William S. Stokes, DVM

You may also be interested in...

Humane Cosmetics Act Lacks FDA Assurance Regarding Alternative Methods

Available non-animal tests for substantiating cosmetic safety "by all appearances are valid," but questions remain as to whether FDA agrees, according to EAS Senior Advisor John Bailey. In the absence of agency guidance on alternative methods and a defined pathway for regulatory acceptance, some industry members are hesitant to get behind the proposed Humane Cosmetics Act in the U.S., the former FDAer suggested in an interview.

News In Brief

NICEATM seeks public comments on priorities for reducing, refining and replacing animal tests. POLA Orbis acquires Jurlique, P&G introduces new beauty and fashion website.

FDA Seeks International Input On Sunscreen Monograph

With a final sunscreen rule targeted for the fall, FDA plans to discuss proposed requirements with regulators from the European Union, Canada and Japan at the International Cooperation on Cosmetics Regulation meeting in Toronto July 13-15

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts